Künstliche Intelligenz in der Forschung

Dieses Buch ist eine Open Access Publikation. Der lange gehegte Traum von künstlicher Intelligenz (KI) wird in unserer Alltagswelt zunehmend Realität. Damit verbinden sich hohe gesellschaftliche Erwartungen, aber auch Sorgen hinsichtlich einer schleichenden Entmündigung des Menschen. Am Beispiel des Forschungssektors lotet dieser Band die Optionen, Entwicklungschancen und Risiken von KI-Techniken für die Zukunft des wissenschaftlichen Erkenntnisprozesses und der darauf beruhenden technischen Entwicklungen aus. Zu diesem Zweck wird zunächst der Stand der KI-Technik und ihrer Anwendungen dargestellt. Es folgen wissenschaftsphilosophische Untersuchungen zur Frage der Ersetzbarkeit des forschenden Menschen durch KI und zu erwartenden Veränderungen in der wissenschaftlichen Forschung. Weitere Abschnitte widmen sich den Folgen für die Arbeitswelt von Forschern/Forscherinnen sowie den durch KI erzeugten neuen Herausforderungen für die rechtliche Regulierung im Spannungsfeld von Wissenschaftsfreiheit und Datenschutz. Der Band schließt mit Empfehlungen für die verantwortlichen Akteure in Wissenschaft, Forschungspolitik und Gesellschaft aus interdisziplinärer Perspektive

The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial

Background: Breast cancer and its treatments are associated with a detrimental effect on bone health. Here we report the results of an exploratory analysis assessing changes in levels of biomarkers of bone metabolism in patients enrolled in the phase IIIb 4EVER study. Methods: The 4EVER trial investigated everolimus in combination with exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer. In this prespecified exploratory analysis, changes in biomarkers of bone turnover were assessed in patients from baseline to weeks 4, 12, and 24. The serum bone markers assessed were procollagen type 1 N-terminal propeptide (P1NP), C-terminal cross-linking telopeptide of type 1 collagen (CTX), osteocalcin, parathyroid hormone (PTH), and 25-hydroxyvitamin D (25-OH-vitamin D). On-treatment changes in bone markers over time were described per subgroup of interest and efficacy outcomes. Results: Bone marker data were available for 241 of 299 enrolled patients. At the final assessment, P1NP, osteocalcin, PTH, 25-OH-vitamin D (all P < 0.001), and CTX (P = 0.036) were significantly decreased from baseline values per the Wilcoxon signed-rank test. At the last assessment (24 weeks or earlier), levels of serum CTX and PTH were significantly lower (P = 0.009 and P = 0.034, respectively) among patients with vs. without prior antiresorptive treatment (ART). Serum CTX levels were significantly lower (P < 0.001), and 25-OH-vitamin D concentrations significantly higher (P = 0.029), at the last postbaseline assessment in patients receiving concomitant ART vs. those without ART. Changes from baseline in PTH and 25-OH-vitamin D concentrations to the final assessment were significantly smaller in patients with prior ART. Lower baseline serum concentrations of osteocalcin and PTH were associated with clinical response (partial vs. non-response) at 24 weeks. High serum levels of CTX and P1NP at baseline were risk factors for progression at 12 weeks. Conclusions: These exploratory analyses support use of everolimus plus exemestane for the treatment of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer, and add to the body of evidence suggesting a potentially favorable impact of everolimus on bone turnover. Trial registration: NCT01626222. Registered 22 June 2012, https://clinicaltrials.gov/ct2/show/NCT01626222. Keywords: Bone health, Bone marker, Breast cancer, Everolimus, Hormone receptor-positive, Mammalian target of rapamyci